FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Background and aims: As no relevant head‐to‐head randomized control trials (RCTs) have been published in CIDP, matching‐adjusted indirect comparisons (MAIC) were conducted to evaluate the efficacy of Panzyga® intravenous immunoglobulin (IVIg) maintenance therapy versus efgartigimod subcutaneous neonatal Fc receptor (FcRn) inhibiting therapy in patients with CIDP.